• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Organigram Enters U.S. Through Acquisition of Collective Project Beverages

    4/1/25 7:47:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email

    Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331607315/en/

    "The acquisition of Collective Project marks yet another strategic milestone towards Organigram's global leadership ambitions. Not only does this acquisition represent our first commercial entry into the fast-growing hemp-derived THC beverage market in the U.S., it also fast tracks our entry into the cannabis beverage category in Canada, a category that we believe is on the cusp of growth at home as well," said Beena Goldenberg, CEO of Organigram.

    Collective Project is an innovative brand launched by Collective Arts, a Hamilton, Ontario-based company founded in 2013. Known for its unique approach to blending craft beverages with art, Collective Arts has featured over 2,000 artists from 40 countries on its products. Collective Project extends this creative ethos into the cannabis market, producing cannabis and hemp-derived infused sparkling juices, teas and sodas.

    "We are pleased to be working with Organigram on this transaction as not only Canada's leading cannabis company but also one that is deeply committed to high-quality products backed by R&D and science-backed innovation," said Matt Johnston, Collective Project co-founder. "The Collective Project brand is under good stewardship, and we expect it to flourish as U.S. and Canadian market expansion unfolds."

    Strategic Rationale

    "In an environment where consumers are shifting away from alcohol, brands that deliver on an enjoyable experience without the negative effects of alcohol will be poised to win in this alternative beverage category that is growing at a rapid rate in the U.S.," said Paolo De Luca, Chief Strategy Officer at Organigram. "We believe that Collective Project's portfolio of cannabis and hemp-derived THC beverages are differentiated, among the best-tasting products in the market today, and are sure to please consumers looking for a satisfying beverage alternative in both the U.S. and Canada."

    The following points highlight the strategic rationale for the acquisition:

    1. Organigram immediately gains a footprint in the U.S. The hemp-derived THC beverage market is currently experiencing significant growth as companies expand their beverages into mass retail. Many U.S. alcohol chains such as Specs, Total Wines and Top Ten Liquors have already embraced the hemp-derived THC beverage category and there is speculation that major convenience and big box retail are considering pilot testing the products. Collective Project is already listed at Top Ten Liquors in Minnesota and Total Wines in North Carolina, South Carolina and Indiana.

    2. Fast tracks Organigram's entry into the beverages category. In Canada, cannabis beverages are believed to have above-average growth opportunities if there are changes to the currently restrictive cannabis dispensary distribution channel. Organigram believes that, among all adult-use cannabis categories in Canada, beverages are most likely to become eligible in the future for on-premise consumption and expanded distribution beyond the current retail-only framework. In the U.S., hemp-derived THC beverages are widely available in traditional retail venues in certain states. This segment is experiencing rapid growth and, according to Euromonitor, is already generating over $1 billion in retail sales, with projections reaching $4 billion by 20281.

    3. Leverages the strength of the Collective Arts brand in the U.S. Collective Project will continue to benefit from the consumer awareness and brand loyalty of Collective Arts, a beloved and top three craft beer brand in Canada, and top three craft import brand in the U.S. Collective Arts is currently active in Florida, New York, Minnesota, Pennsylvania, Virginia and Puerto Rico. Also, Collective Project will benefit from deep artist community roots in the U.S. market.

    4. Organigram will have the opportunity to leverage the relationships and infrastructure that Collective Arts has built in the U.S. to fast-track the launch of our own portfolio of hemp derived THC beverages.

    5. Organigram can start consolidating U.S. revenue. Unlike state-regulated cannabis at the federal level, hemp is regulated under the 2018 Farm Bill and is federally legal. Some states, like Minnesota and Florida, have embraced hemp-derived THC products for beverages and edibles, creating near market opportunities. Organigram believes that enough states are currently active in hemp-derived THC beverages to allow it to establish a material U.S. market position over time.

    6. Highly complementary product portfolio. Fills the last major category gap in the Organigram portfolio where Organigram will immediately capture 5.6% of the beverage category in Canada with strong upside potential due to portfolio and distribution expansion and the opportunity for Organigram to bring its proprietary FAST™ nano emulsion technology to beverage products.

    7. Ability to leverage Canadian sales team and sales agent to deliver distribution gains across Canada. Opportunity for geographic expansion beyond Ontario and CPL's current provincial footprint, as well as to significantly improve distribution within existing markets by securing listings with major retailers that do not yet carry the brand.

    Product Availability

    Collective Project products are available in both Canada and the U.S. and feature a premium flavour-forward lineup of beverages made with real fruit juice, no artificial sweeteners, and featuring elevated flavour profiles. In addition, the brand's approach to packaging design supports the artist community through their ever-changing artist-designed labels, reflecting the brand's commitment to fostering creativity and collaboration.

    Collective Project Product Portfolio:

    • Blood Orange Vanilla Yuzu (Canada and U.S.)
    • Raspberry Vanilla (Canada and soon in the U.S.)
    • Mango Coconut Pineapple (Canada and U.S.)
    • Cherry Vanilla (Canada)
    • White Peach Cardamom (Canada)
    • Mango Peach Yuzu (Canada)
    • Blueberry Elderberry White Tea (Canada)

    In addition to Collective Project, CPL has recently launched "Fetch" in Canada featuring a lineup of accessibly priced sodas in popular flavours with both regular and zero sugar options.

    Fetch Product Line:

    • Classic Cola Zero (Available in Canada)
    • Cream Soda (Available in Canada)
    • Lemon-Lime Zero (Available in Canada)
    • Classic Cola (Available soon in Canada)
    • Cream Soda Zero (Available soon in Canada)
    • Lemon-Lime (Available soon in Canada)

    In the U.S., Collective Project products launched in late 2024 and are currently available for sale in Minnesota, Ohio, North Carolina, South Carolina, Florida, Texas, Indiana, Tennessee, Georgia and Kentucky, including in key retailers such as Total Wines and Top 10 Liquors. By the end of the year, it is expected that products will also be distributed in Connecticut, New Jersey, Illinois, and Alabama. In Canada, the products are currently available in Ontario, British Columbia, Saskatchewan, Newfoundland and Nova Scotia with distribution in additional provinces to follow in the coming months.

    Transaction Details

    • Organigram has acquired all the issued and outstanding shares of CPL, on a debt free basis, for C$6.2 million cash of which C$6.0 million is attributable to the beverage business ("Original Consideration") and C$0.2 million attributable to all other cannabis categories that CPL is engaged in (vapes and edibles).
    • Milestone and earnout payments thereafter (collectively "Contingent Consideration"), if applicable, are subject to performance in the beverage category only.
    • Milestone payments of C$2.0 million each in cash are payable if CPL achieves "cumulative depleted wholesale sales2" of at least US $500,000 from inception to June 30, 2025 ("Milestone 1") and "cumulative depleted wholesale sales2" of at least US $1 million from inception to September 30, 2025 ("Milestone 2") in each case from its U.S. hemp-derived beverage business.
    • The first eligible earnout payment ("First Earnout"), if applicable, shall be paid by calendar 2025 year-end, based on 2.5 times trailing twelve months net revenue to September 30, 2025, less any consideration paid to date including the Original Consideration, Milestone 1 (if applicable) and Milestone 2 (if applicable). The First Earnout, if applicable, is expected to be paid 50% in cash and 50% in Organigram share consideration priced at the five-day TSX VWAP the day prior to settlement.
    • The second eligible earnout payment ("Second Earnout"), if applicable, shall be paid by calendar 2026 year-end, based on 2.5 times trailing twelve months net revenue to September 30, 2026, less any consideration paid to date including the Original Consideration, Milestone 1 (if applicable), Milestone 2 (if applicable) and the First Earnout (if applicable). The Second Earnout, if applicable, is expected to be paid 50% in cash and 50% in Organigram share consideration priced at the five-day TSX VWAP the day prior to settlement.
    • Contingent Consideration for the beverage business in all cases shall be capped at C$24 million.
    • While the Original Consideration of C$6.2 million will not be taken from the Jupiter strategic investment pool as CPL is currently substantially a Canadian business, some of the future milestone or earn-out payments, if any, may be eligible for drawdowns from the Jupiter strategic investment pool.

    Websites and Social Media:

    To learn more, please visit:

    • Canadian and U.S. websites: www.collectiveproject.ca or www.collectiveproject.com respectively.
    • Instagram account: https://www.instagram.com/collectiveprojectusa/

    About Organigram

    Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada, and Motif Labs Ltd., a licensed cannabis processor.

    Organigram is focused on producing high-quality cannabis for adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

    Forward-Looking Information

    This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include performance of the business post-closing, market factors, regulatory changes, consumer demand and preferences and factors and risks disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Examples of forward-looking statements in this news release include, among others, (i) the structure and terms of the transaction, including potential milestone and earnout payments; (ii) the growth opportunities for cannabis beverages in Canada and the U.S.; (iii) the Company's launch of its own portfolio of hemp-derived THC beverages; and (iv) Organigram's ability to establish a material U.S. market position over time for hemp-derived THC products in beverages and edibles. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release is made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

    1 https://www.euromonitor.com/article/fizz-with-a-buzz-the-rise-of-cannabis-drinks-in-the-us

    2 Cumulative depleted wholesale sales refers to the total value of product sold through from distributors to retailers, measured from the inception of such sales to the applicable milestone date.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250331607315/en/

    For Media enquiries:

    Megan McCrae, Senior Vice President – Global Brands and Corporate Affairs [email protected]

    Max Schwartz – Director of Investor Relations [email protected]

    Get the next $OGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      12/10/24 7:10:15 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      9/3/24 9:30:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      1/25/24 5:23:26 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

      3/24/25 8:30:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Craig Harris to Board of Directors

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

      7/29/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Karina Gehring to Board of Directors

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

      1/19/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on OrganiGram

      Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

      7/17/24 12:18:49 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Alliance Global Partners

      Alliance Global Partners upgraded OrganiGram from Neutral to Buy

      4/15/24 8:40:01 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Stifel

      Stifel upgraded OrganiGram from Hold to Buy

      1/13/23 7:36:46 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global's Collective Project Wins Big at the 2025 High Spirits Awards in California

      Wins gold medal for Blood Orange, Yuzu & Vanilla and platinum medal for Mango, Pineapple & Coconut Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce that its recently acquired business, Collective Project, has won recognition at the 2025 High Spirits Awards only a few short months following the launch of the brand in the U.S. The brand received a gold award for Blood Orange, Yuzu & Vanilla and a platinum award for Mango, Pineapple & Coconut hemp-derived THC beverages. High Spirits Awards is a competition launched by L.A. Spirits Awards in 2023 to identify and reward excellence among the growi

      5/7/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export Awards

      Award recognizes exceptional export growth, product innovation, and global market leadership Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), ("the Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce it has been named Exporter of the Year by Opportunities New Brunswick ("ONB") as part of the 2025 New Brunswick Export Awards, ONB's flagship annual event recognizing the successes and innovative approaches of New Brunswick's many exporting companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505021217/en/ This honour recognizes Organigram's significant growth in international cannab

      5/5/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    SEC Filings

    See more
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/12/25 7:39:04 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/7/25 9:38:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/5/25 11:48:28 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Financials

    Live finance-specific insights

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

        Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

      5/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Enters U.S. Through Acquisition of Collective Project Beverages

      Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026. This press release features multimedia. View the full

      4/1/25 7:47:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care